A Phase 1b/2 Study investigated the efficacy of the Bruton tyrosine kinase inhibitor Ibrutinib and the PD-L1 inhibitor Durvalumab in patients with pretreated solid tumors which includes 28 non-small cell lung cancer patients. The gene discussed is BTK; the disease is non-small cell lung carcinoma.